Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
K Xu, J Liang, T Zhang, Z Zhou, D Chen… - Thoracic …, 2021 - Wiley Online Library
Background Concurrent epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐
TKI) with radiotherapy in patients with EGFR‐mutant unresectable stage III non‐small cell …
TKI) with radiotherapy in patients with EGFR‐mutant unresectable stage III non‐small cell …
Management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis
A Passaro, M Di Maio, E Del Signore, B Gori… - Clinical Lung Cancer, 2014 - Elsevier
Introduction Nonhematologic toxicities are frequently observed in patients receiving
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non …
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials
WX Qi, YJ Sun, Z Shen, Y Yao - Journal of chemotherapy, 2015 - Taylor & Francis
Purpose: To assess the risk of interstitial lung disease (ILD) with epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. Method …
receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib, erlotinib, and afatinib. Method …
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review
XW Yang, K Yang, KY Kuang - Current oncology reports, 2014 - Springer
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been
extensively investigated in previously treated advanced non-small-cell lung cancer …
extensively investigated in previously treated advanced non-small-cell lung cancer …
[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials
L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - Elsevier
Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Y Zhao, B Cheng, Z Chen, J Li, H Liang, Y Chen… - Critical Reviews in …, 2021 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
[HTML][HTML] Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis
Y Zhang, J Sheng, Y Yang, W Fang, S Kang, Y He… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background: To answer which epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) is the best choice for advanced non-small cell lung cancer (NSCLC) EGFR …
(EGFR-TKI) is the best choice for advanced non-small cell lung cancer (NSCLC) EGFR …
[HTML][HTML] The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
相关搜索
- meta analysis lung cancer
- egfr tyrosine kinase inhibitors
- egfr tkis lung cancer
- egfr tyrosine radiation pneumonitis
- kinase inhibitors radiation pneumonitis
- meta analysis egfr tkis
- egfr tyrosine clinical outcomes
- kinase inhibitors clinical outcomes
- nsclc patients egfr tki
- toxicity profile lung cancer
- meta analysis gefitinib and erlotinib
- egfr tyrosine unresectable stage
- egfr tkis network metaanalysis
- egfr mutation asian patients
- kinase inhibitors unresectable stage
- risk stratification egfr tki